Announced Wed, 15 Jul · 15:30 IST
Board meeting on July 31 to approve Q1 FY27 results
Results View source PDF
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-3.2%1-day move
₹2305.20
prior close
₹2313.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.0-0.9-1.0-1.3-3.2-2.7-2.7-4.3-4.4-4.6————
Up moveDown movePending
AI summary
Glenmark Pharmaceuticals has informed stock exchanges that its Board of Directors will meet on Friday, July 31, 2026 to consider and approve the Unaudited Financial Results, both Standalone and Consolidated, for the quarter ended June 30, 2026. The trading window for designated persons remains closed from July 1, 2026 till August 2, 2026 and reopens on August 3, 2026. Results will be filed with the exchanges and posted on the company website after the meeting.
Likely market impact
Routine pre-results intimation. No new financial data yet; investors should watch for Q1 results on July 31, 2026.